A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

Julia Katharina Schwarze; Gil Awada; Louise Cras; Ramses Forsyth; Ivan Van Riet; Bart Neyns

A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

Julia Katharina Schwarze, Gil Awada, Louise Cras, Ramses Forsyth, Ivan Van Riet, Bart Neyns

Research output: Chapter in Book/Report/Conference proceeding › Meeting abstract (Book)

Original language	English
Title of host publication	Journal of Clinical Oncology
Publisher	American Society of Clinical Oncology
Publication status	Published - May 2019
Event	ASCO Annual Meeting 2019 - Chicago, Illinois, USA, Chicago, United States Duration: 31 May 2019 → 4 Jun 2019

Conference

Conference	ASCO Annual Meeting 2019
Country/Territory	United States
City	Chicago
Period	31/05/19 → 4/06/19

Access to Document

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e14012

Cite this

Schwarze, J. K., Awada, G., Cras, L., Forsyth, R., Van Riet, I., & Neyns, B. (2019). A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. In Journal of Clinical Oncology Article e14012 American Society of Clinical Oncology. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e14012

Schwarze, Julia Katharina ; Awada, Gil ; Cras, Louise et al. / A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. Journal of Clinical Oncology. American Society of Clinical Oncology, 2019.

@inbook{ce57825f46aa4c659ddfbea9b3585cea,

title = "A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.",

author = "Schwarze, {Julia Katharina} and Gil Awada and Louise Cras and Ramses Forsyth and {Van Riet}, Ivan and Bart Neyns",

year = "2019",

month = may,

language = "English",

booktitle = "Journal of Clinical Oncology",

publisher = "American Society of Clinical Oncology",

address = "United States",

note = "ASCO Annual Meeting 2019 ; Conference date: 31-05-2019 Through 04-06-2019",

}

Schwarze, JK , Awada, G, Cras, L, Forsyth, R , Van Riet, I & Neyns, B 2019, A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. in Journal of Clinical Oncology., e14012, American Society of Clinical Oncology, ASCO Annual Meeting 2019, Chicago, United States, 31/05/19. <https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e14012>

A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. / Schwarze, Julia Katharina ; Awada, Gil; Cras, Louise et al.
Journal of Clinical Oncology. American Society of Clinical Oncology, 2019. e14012.

Research output: Chapter in Book/Report/Conference proceeding › Meeting abstract (Book)

TY - CHAP

T1 - A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

AU - Schwarze, Julia Katharina

AU - Awada, Gil

AU - Cras, Louise

AU - Forsyth, Ramses

AU - Van Riet, Ivan

AU - Neyns, Bart

PY - 2019/5

Y1 - 2019/5

M3 - Meeting abstract (Book)

BT - Journal of Clinical Oncology

PB - American Society of Clinical Oncology

T2 - ASCO Annual Meeting 2019

Y2 - 31 May 2019 through 4 June 2019

ER -

Schwarze JK , Awada G, Cras L, Forsyth R , Van Riet I , Neyns B. A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors. In Journal of Clinical Oncology. American Society of Clinical Oncology. 2019. e14012